Paper Details

  1. Home
  2. Paper Details

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

Author: HughesCarmel, LimWei Yin, LoyClement, McGuinnessBernadette, ParsonsCarole, PassmorePeter, WardStephanie A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Dementia is a brain disorder that causes memory loss, thinking problems, and changes in behavior. Medications like donepezil, galantamine, rivastigmine, and memantine are commonly used to help manage dementia symptoms and slow its progression. However, we need more research to understand the long-term effects of these medications, especially in severe dementia, and when to stop treatment.
Paper Details　
Original Abstract of the Article :
Dementia is a progressive syndrome characterised by deterioration in memory, thinking and behaviour, and by impaired ability to perform daily activities. Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094886/

データ提供：米国国立医学図書館（NLM）

Dementia: A Journey Through the Fog of Memory

Dementia, a progressive neurodegenerative disorder, often feels like a journey through a fog of memory, where the familiar becomes lost and the future uncertain. This study, a journey through the challenging landscape of dementia, explores the use of cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and memantine in managing dementia symptoms. Imagine a caravan of caregivers, equipped with different medications, seeking to alleviate the symptoms and improve the quality of life for individuals with dementia. This study examines the use of these medications, addressing key questions about their long-term effectiveness, withdrawal effects, and the optimal timing for discontinuing treatment.

Navigating the Desert of Memory Loss

The study's findings, like a flickering candle in the darkness of dementia, shed light on the complex issues surrounding the use of cholinesterase inhibitors and memantine. While these medications can provide temporary symptom relief, there are ongoing questions about their long-term benefits and potential risks. This research underscores the importance of individualized treatment plans, carefully considering the needs and circumstances of each patient.

Finding Hope in the Desert

This study, like a map guiding us through the challenging terrain of dementia, highlights the need for ongoing research and a thoughtful approach to managing this complex disorder. While there is no cure for dementia, this study reminds us that we must continue to explore new treatments and strategies to improve the lives of individuals affected by this debilitating condition. As we navigate the desert of memory loss, we must strive to find hope and support for patients and their loved ones.

Dr.Camel's Conclusion

This study explores the use of cholinesterase inhibitors and memantine in managing dementia symptoms, highlighting the need for individualized treatment plans and ongoing research to improve the lives of those affected by this debilitating condition.

Date :
  1. Date Completed 2022-05-26
  2. Date Revised 2023-02-16
Further Info :

Pubmed ID

35608903

DOI: Digital Object Identifier

PMC8094886

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.